You are here: Industry Insights > PTx

News List

Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study europeanpharmaceuticalreview
March 26, 2021
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
New partnership to explore potential biodefence applications for FX-06 europeanpharmaceuticalreview
March 08, 2021
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.
Leukine Trial in Hospitalized COVID-19 Patients Meets Primary Endpoint americanpharmaceuticalreview
March 03, 2021
Partner Therapeutics (PTx) announced top-line results of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine® (sargramostim, yeast-derived recombinant human GM-CSF) ...
PTx Announces Contract with DOD for Leukine for COVID-19 Associated Acute Hypoxemia americanpharmaceuticalreview
August 12, 2020
Partner Therapeutics (PTx) anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD).